Associations between autoimmune conditions and hepatobiliary cancer risk among elderly US adults

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift


Growing evidence suggests that people with autoimmune conditions may be at increased risk of hepatobiliary tumors. In the present study, we evaluated associations between autoimmune conditions and hepatobiliary cancers among adults aged ≥66 in the United States. We used Surveillance, Epidemiology, and End Results (SEER)-Medicare data (1992–2013) to conduct a population-based, case–control study. Cases (n = 32,443) had primary hepatobiliary cancer. Controls (n = 200,000) were randomly selected, cancer-free adults frequency-matched to cases by sex, age and year of selection. Using multivariable logistic regression, we calculated odds ratios (ORs) and 95% confidence intervals (CIs) for associations with 39 autoimmune conditions identified via Medicare claims. We also conducted separate analyses for diagnoses obtained via inpatient versus outpatient claims. Sixteen conditions were associated with at least one hepatobiliary cancer. The strongest risk estimates were for primary biliary cholangitis with hepatocellular carcinoma (OR: 31.33 [95% CI: 23.63–41.56]) and primary sclerosing cholangitis with intrahepatic cholangiocarcinoma (7.53 [5.73–10.57]), extrahepatic cholangiocarcinoma (5.59 [4.03–7.75]), gallbladder cancer (2.06 [1.27–3.33]) and ampulla of Vater cancer (6.29 [4.29–9.22]). Associations with hepatobiliary-related conditions as a group were observed across nearly all cancer sites (ORs ranging from 4.53 [95% CI: 3.30–6.21] for extrahepatic cholangiocarcinoma to 7.18 [5.94–8.67] for hepatocellular carcinoma). Restricting to autoimmune conditions diagnosed via inpatient claims, 6 conditions remained associated with at least one hepatobiliary cancer, and several risk estimates increased. In the outpatient restricted analysis, 12 conditions remained associated. Multiple autoimmune conditions are associated with hepatobiliary cancer risk in the US Medicare population, supporting a shared immuno-inflammatory etiology to these cancers.


  • Emma E. McGee
  • Felipe A. Castro
  • Eric A. Engels
  • Neal D. Freedman
  • Ruth M. Pfeiffer
  • Leticia Nogueira
  • Rachael Stolzenberg-Solomon
  • Katherine A. McGlynn
  • Kari Hemminki
  • Jill Koshiol
Enheter & grupper
Externa organisationer
  • National Cancer Institute
  • American Cancer Society
  • German Cancer Research Centre
  • Roche Innovation Center

Ämnesklassifikation (UKÄ) – OBLIGATORISK

  • Cancer och onkologi
  • Reumatologi och inflammation


Sidor (från-till)707-717
TidskriftInternational Journal of Cancer
Utgåva nummer4
Tidigt onlinedatum2018 aug 28
StatusPublished - 2019 feb 15
Peer review utfördJa